Showing results (111-120 of 137) with videos related to

Sort By:
Pageof 14
Breast (Edinburgh, Scotland)|December 4, 2022
Effect of palbociclib plus endocrine therapy on time to chemotherapy across subgroups of patients with hormone receptor‒positive/human epidermal growth factor receptor 2‒negative advanced breast cancer: Post hoc analyses from PALOMA-2 and PALOMA-3Hope S Rugo, Seock-Ah Im, Anil A Joy, et al.
Oncogene|December 20, 2025
Chromosome centromere copy number amplification associated with exceptional response in HER2-positive metastatic breast cancer patientsCharlotte Andrieu, Jojanneke Stoof, Dalal AlSultan, et al.
The New England Journal of Medicine|December 14, 2016
Palbociclib and Letrozole in Advanced Breast CancerRichard S Finn, Miguel Martin, Hope S Rugo, et al.
Breast Cancer Research and Treatment|September 14, 2015
Economic impact of 21-gene recurrence score testing on early-stage breast cancer in IrelandLillian Smyth, Geoff Watson, Elaine M Walsh, et al.
Dysphagia|August 10, 2021
A Retrospective Analysis of Swallowing Function and Physiology in Patients Living with DementiaAshwini M Namasivayam-MacDonald, Naga Alomari, Lauren Attner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 22, 2024
Overall Survival With Palbociclib Plus Letrozole in Advanced Breast CancerDennis J Slamon, Véronique Diéras, Hope S Rugo, et al.
Journal of the National Cancer Institute|May 15, 2023
Ten-year update: NRG Oncology/National Surgical Adjuvant Breast and Bowel Project B-42 randomized trial: extended letrozole therapy in early-stage breast cancerEleftherios P Mamounas, Hanna Bandos, Priya Rastogi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 20, 2024
Breast Cancer Index and Prediction of Extended Aromatase Inhibitor Therapy Benefit in Hormone Receptor-Positive Breast Cancer from the NRG Oncology/NSABP B-42 TrialEleftherios P Mamounas, Hanna Bandos, Priya Rastogi, et al.
ESMO Open|January 21, 2023
Cardiac safety of dual anti-HER2 blockade with pertuzumab plus trastuzumab in early HER2-positive breast cancer in the APHINITY trialE de Azambuja, E Agostinetto, M Procter, et al.
Current Oncology (Toronto, Ont.)|March 27, 2024
Real-World Analysis of the Clinical and Economic Impact of the 21-Gene Recurrence Score (RS) in Invasive Lobular Early-Stage Breast Carcinoma in IrelandLynda M McSorley, Mehala Tharmabala, Fathiya Al Rahbi, et al.
Pageof 14